Assessment of Metabolic and Pathological Response to Treatment With RCT and ImT Before Surgery in Locally Advanced Esophageal and Gastro-esophageal Junction Cancer: ARTemIS-Eso, a Three-level, Open-label, Phase I-II Study
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Monalizumab (Primary) ; Fluorouracil; Oxaliplatin
- Indications Adenocarcinoma; Gastrointestinal cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ARTemIS-Eso
- 18 Dec 2017 Planned End Date changed from 1 Mar 2021 to 11 Dec 2017.
- 18 Dec 2017 Planned primary completion date changed from 1 Mar 2019 to 11 Dec 2017.
- 18 Dec 2017 Status changed from recruiting to withdrawn prior to enrolment.